Skip to main content

Table 1 Baseline AAV patient characteristics by treatment group

From: Favorable efficacy of rituximab in ANCA-associated vasculitis patients with excessive B cell differentiation

VariablesRituximab group, n = 34IV-CY group, n = 20p value
Age (years)70.4 (8.4)70.9 (8.4)0.86
Gender, n (% female)19 (55.9%)10 (50.0%)0.78
Disease duration (month)3 (2–5)4 (1–7)0.93
New onset, n (%)34 (100.0%)20 (100.0%)1.00
ANCA-positive at diagnosis, n (%)
 Proteinase 3 ANCA4 (11.8%)0 (0.0%)0.28
 Myeloperoxidase-ANCA26 (76.5%)18 (90.0%)0.29
 Proteinase 3 + myeloperoxidase-ANCA3 (8.8%)1 (5.0%)1.00
ANCA-associated vasculitis type, n (%)  0.24
 MPA19 (55.9%)15 (75.0%) 
 GPA15 (44.1%)5 (25.0%) 
BVAS17.4 (6.5)15.1 (4.6)0.15
Organ involvement, n
 Cutaneous involvement200.52
 Mucous membranes and eyes321.00
 Ear, nose, and throat1161.00
 Pulmonary involvement27150.74
 Renal involvement28180.75
 Neurologic involvement1130.21
GC dose at base line56.3 (11.5)61.6 (16.7)0.17
  1. Values listed as mean (SD) and median (minimum-maximum) unless otherwise stated. The statistical difference was determined by Student’s t test and Mann-Whitney’s U test, with chi-square test used for nominal variables. Difference with p < 0.05 was considered significant